Dry Skin (Xerosis)

This research aims to evaluate the treatment of deucravacitinib in adults with inflammatory epidermal genodermatoses, including conditions such as Epidermolysis Bullosa Simplex and various ichthyoses. The study focuses on assessing the efficacy and safety of this treatment for these rare skin disorders. It is a phase 2, open-label trial lasting 44 weeks conducted at a single center. Participants will undergo a treatment schedule divided into three periods: an initial 16-week treatment (challenge period), followed by a 12-week break from treatment (dechallenge period), and a second 16-week treatment period (rechallenge period). During these phases, participants will receive deucravacitinib and be closely monitored. The study uses a challenge-dechallenge-rechallenge design to evaluate treatment effects. Throughout the study, participants will attend eight visits where doctors will check their vital signs, perform clinical exams, and assess treatment adherence and any side effects. Participants will also complete questionnaires and provide blood samples. Researchers will primarily measure the efficacy of deucravacitinib at week 44 and monitor safety. The total participation duration is 44 weeks, ending with a final evaluation.

This research aims to evaluate the safety and effectiveness of the Thermage FLX System, a device designed to improve lines and wrinkles and lift and tighten loose skin in adults aged 30 to 60 years. The study is a prospective, randomized, multicenter trial conducted at approximately 10 sites in North America and China. It focuses on mild-to-moderate skin laxity and wrinkles on the neck, abdomen, upper arms, and face. Participants are randomly assigned to receive treatment with the Thermage FLX device either on day 1 or day 90. The study compares treated participants with an untreated control group to assess improvements in skin appearance. The treatment involves a non-invasive radiofrequency procedure designed for dermatological use. During the 6-month (26-week) study, participants will attend scheduled visits for assessments by independent blinded evaluators. Researchers will measure the primary outcome at 90 days and secondary outcomes at 180 days after treatment. Safety, tolerability, and skin improvements will be closely monitored through various clinical evaluations and participant follow-up throughout the study period.

Researchers are evaluating the effects of a fish oil concentrate called EPAX Omega 3-9-11 on skin function. This study aims to determine if this combination of long chain mono-unsaturated fatty acids and omega-3 can improve skin health by reducing inflammation, redness, and improving the skin's barrier function. The research involves healthy adults aged 35 to 65 with a history of atopic skin prone to redness or dryness. Participants will be randomly assigned to one of three groups: a placebo group taking 1g corn oil capsules, a low dose group receiving 2g of Omega 3-9-11 oil, or a high dose group receiving 4g of Omega 3-9-11 oil daily. They will take these capsules for three months, with measurements taken at the start, 6 weeks, and 12 weeks. During the study, participants will undergo biophysical measurements of their face and inner forearm to assess skin erythema (redness) and hydration. Researchers will also monitor skin health through the Omega-3 index and other skin parameters adjusted for placebo effects. The study includes safety monitoring and requires participants to avoid other fish oil or lipid-based supplements during the trial. The total participation lasts three months, with evaluations at regular intervals.

Researchers are developing and managing the AnovaOS Network Powered Patient Registry to collect real-world patient data across various diseases globally. This registry aims to capture meaningful clinical information on diagnosis, infection course, treatments, and outcomes to enhance understanding and support future clinical trials and observational studies. The registry serves as a resource to better understand, prevent, diagnose, and treat diverse health conditions. Participants' data will be gathered through this registry, which can also be used to recruit individuals for clinical trials and observational studies on promising therapies. The registry collects ongoing information on patients' health status and treatments, enabling long-term monitoring and analysis. This observational study does not involve administering treatments but focuses on data collection and management. Participants will provide information through questionnaires or instruments, either personally or via an informed proxy, with an expected follow-up once per year. The research team will assess natural history, clinical effectiveness, safety, and quality of care over a period of five years. The registry includes patients with a wide range of conditions, and participation requires informed consent and the ability to complete follow-up data collection.

Dandruff is a common scalp condition affecting people of all genders and ethnicities, linked to imbalances in the skin's microflora, especially involving the Malassezia genus, Propionibacterium acnes, and Staphylococcus epidermidis. This trial investigates the effects of an anti-fungal lotion containing NaP and antioxidant VitCG on reducing dandruff and rebalancing the scalp microbiome, comparing it to a vehicle lotion and a reference anti-fungal lotion with Octopirox. The study is sponsored by L'Oreal and aims to understand how these treatments impact scalp health at a microbiological level. Participants will be randomly assigned to one of three groups receiving either the experimental NaP1%+VitCG3% leave-on lotion, a vehicle lotion, or a reference Octopirox 0.25% lotion, all used with a neutral shampoo. The treatments are applied as leave-on lotions, and the study evaluates their effects over a 28-day period. The trial includes detailed scalp evaluations and sample collections to analyze changes in dandruff severity and microbial populations. Volunteers aged 18 to 60 with moderate to severe dandruff will attend study visits for assessments on day 0 and day 28, where dandruff scores and microbiome samples will be taken. Participants will have specific scalp zones sampled and shaved for analysis. Researchers will measure dandruff severity and microbial species changes, monitor safety, and ensure adherence by providing all study products and requiring consistent shampoo use during the study. The total participation duration is 28 days, with evaluations focusing on dandruff status and microbiome balance.

Researchers are evaluating a new artificial intelligence (AI) tool designed to assist primary care providers in assessing skin conditions. This AI-powered dermatology image reference app works with a smartphone to provide reference images, helping providers make diagnoses using their medical training. The study aims to compare diagnoses made by primary care providers using the AI tool to those of a panel of dermatologists, considered the gold standard. The research is supported by the Advanced Research Projects Agency for Health (ARPA-H) and focuses on improving diagnostic accuracy and care in real-world clinical settings. The study involves primary care providers using the Belle AI tool, which analyzes images captured via a smartphone app and identifies over 2,000 skin conditions based on a large image database. Providers use the app during patient visits to capture images and receive differential diagnoses, which they review before making final decisions. After the initial visit, participants receive notifications to submit follow-up images using the app over a two-week period. Providers reassess diagnoses based on updated AI analysis, and follow-up visits may be scheduled or canceled depending on results. Providers receive training on the app and give feedback through surveys. Participants present with a primary dermatological complaint and consent to study procedures, including using the smartphone app to submit images. Researchers monitor diagnosis accuracy compared to a dermatology review committee consensus and assess economic impact and provider experience. The study lasts about 14 days per participant, with ongoing documentation in electronic medical records and continuous case review to determine care needs or resolution.

Increasing heat exposure caused by climate change is affecting communities worldwide, especially those living in poor housing conditions such as informal settlements and low-income households. This research aims to study the impact of applying sunlight-reflecting cool roof coatings on indoor temperatures and overall health. The trial is a global, multi-center, cluster-randomized controlled study conducted in five urban climate hotspots across Africa, Asia, Latin America, and Oceania, where heat exposure and vulnerable housing conditions pose significant health risks. The study compares households that receive a cool roof coating, which reflects sunlight and reduces indoor heat, with those that keep their original roofs. The cool roof coating works by reflecting ultraviolet and visible sunlight and radiating absorbed heat, thus lowering indoor temperatures and energy use. The trial will run over a 12-month period, including the hottest months of the year, to measure the effects on health, indoor environment, and economic outcomes. Participants will undergo repeated measurements including resting heart rate, blood glucose control, depression symptoms, and various health and environmental factors over the course of the study. Data will be collected at baseline and multiple times during the hottest months and alternate months. Researchers will monitor indoor air temperature, humidity, heat index, and household energy use continuously. The study seeks to provide evidence on whether cool roofs can improve physical, mental, and social wellbeing in vulnerable populations facing extreme heat.

Researchers are evaluating how well Botulinum Toxin Type A works to reduce facial wrinkles and if it is safe for people aged 20 to 65 years. This study aims to find the best dose that improves the appearance of wrinkles with minimal side effects, while also making cosmetic treatments more affordable and accessible across different economic backgrounds. The research is conducted using a controlled, open-label approach to gather detailed information on treatment effects and patient satisfaction. Participants will receive an initial treatment of Botulinum Toxin Type A after screening and baseline facial muscle assessment. Touch-up treatments will be given every three weeks for six months, with assessments of facial movement control at three weeks and evaluation of wrinkle longevity and immune response at six months. This treatment cycle will repeat after six months for a second dose, continuing up to one year. During the study, participants will undergo regular evaluations to measure changes in facial wrinkles, wrinkle severity, and overall facial appearance for up to two years. Skin reactions will also be monitored throughout the study. Researchers will collect detailed records of dosages and treatment effects to understand the safety and cosmetic outcomes. The total participation time includes treatment and follow-up assessments to provide comprehensive long-term data.

This research aims to explore the connections between dietary intake, markers of cardiometabolic health, and gut microbiota composition in adults living in Singapore. It addresses the lack of studies focusing on Asian populations by considering their unique genetic, metabolic, and dietary characteristics. The goal is to better understand how diet influences health outcomes specific to this population and to contribute to improved dietary guidelines. The study is observational and cross-sectional, involving adults aged 21 to 80 years. Participants are grouped by age into younger (21-64 years) and middle-aged to older adults (65-80 years). Researchers collect detailed dietary information over seven days and measure various health markers, including blood pressure, blood lipids, fasting glucose, endothelial progenitor cell counts, and several fecal biomarkers related to gut health. Additional assessments cover sleep quality, cognitive function, skin carotenoid levels, physical activity, stress, anxiety, depression, vision, and advanced skin glycation end products. Participants will attend a study visit where blood and fecal samples are collected alongside completing questionnaires and physical assessments. Researchers evaluate primary outcomes such as dietary intake and multiple health biomarkers on the first day, while secondary outcomes include sleep, mental health, physical activity, and vision measures. The study provides valuable insights into diet’s impact on cardiometabolic and gut health and lasts from the start visit until all assessments are completed, with no treatment administered.

Researchers are evaluating Autologous Adipose Cell Therapy to improve skin rejuvenation and hair restoration. This therapy aims to overcome the limitations of traditional fat grafting and dermal fillers by isolating early-stage fat cells for better distribution and longer-lasting effects. The study focuses on assessing the safety, feasibility, and effectiveness of this therapy for conditions like wrinkles, fine lines, skin elasticity loss, pigmentation, hair thinning, and hair loss. Participants will receive the Autologous Adipose Cells therapy treatment, which involves processing fat cells from their own body to enhance skin and hair appearance. The therapy is monitored by the primary investigator for up to 25 weeks to evaluate outcomes. This study includes only one treatment group receiving this biological intervention. During the study, participants will undergo various assessments including imaging, satisfaction surveys, and evaluation reports from the first visit before treatment through the last follow-up visit between weeks 16 and 25. The plastic surgeon will monitor treatment effects and safety over a six-month period. The total involvement spans from initial treatment to multiple follow-ups to track skin and hair improvements and participant satisfaction.